Analyst predicts blockbuster potential for Biomarin's growth hormone

The US-based biotech company Biomarin is edging closer to the launch of dwarfism drug Voxzogo and one analyst sees signs of a potential blockbuster. The US Food and Drug Administration is expected to reach a decision this week.
Photo: Anders Rye Skjoldjensen
Photo: Anders Rye Skjoldjensen
BY ULRICH QUISTGAARD, TRANSLATED BY DANIEL PEDERSEN

Within the week, Biomarin will know whether it has received the green light to market Voxzogo – its treatment for achondroplasia, also known as dwarfism – from the US Food and Drug Administration (FDA).

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading